Loading...
Loading...
NBSE| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 7,723.4K |
| Operating I/L | -7,723.4K |
| Other Income/Expense | 91.5K |
| Interest Income | 106.7K |
| Pretax | -7,631.9K |
| Income Tax Expense | -91.5K |
| Net Income/Loss | -7,540.4K |
NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company specializing in developing therapies for rare genetic diseases and cancers caused by mutant genes. The company's proprietary PATrOL platform focuses on addressing Huntington's disease, myotonic dystrophy, and other genetic disorders, as well as cancer and oncology applications. Their lead programs include NT0100 for Huntington's disease, NT0200 for myotonic dystrophy type 1, and NT0300 for targeting the mutated KRAS gene.
